FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Apricus Selling Vitaros ED Cream Rights

Apricus Biosciences says it cant afford to do what FDA says is needed for a Vitaros NDA resubmission and it is shopping the U.S. rights to the erectil...

Human Drugs

7 Observations in Denver Solutions FDA-483

FDA releases an FDA-483 with seven observations from an inspection at Englewood, CO-based Denver Solutions outsourcing facility.

Human Drugs

FDA Broadens Jardiance Heart Failure Indication

FDA approves a new Jardiance indication to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.

Medical Devices

Viz.ai Aneurysm Module Cleared by FDA

FDA clears a Viz.ai 510(k) for the Viz Aneurysm module and its use on the Viz Intelligent Care Coordination Platform for detecting suspected cerebral ...

Human Drugs

United Therapeutics NDA Review Extension for Tyvaso

FDA extends its review of a United Therapeutics NDA resubmission for Tyvaso DPI (inhaled treprostinil) after receiving an information request letter f...

Federal Register

Proposal to Harmonize Device QSR with ISO 13485

Federal Register notice: FDA publishes a proposed rule to amend medical device current GMP requirements of the Quality System Regulation to align more...

Human Drugs

FDA Opens Compounding MOU Study

FDA says it will open notice-and-comment rulemaking to analyze the impact of a memorandum of understanding between it and states on the distribution o...

Medical Devices

Comments on Physiologic Closed-Loop Guidance

Three stakeholders comment on an FDA draft guidance on technical considerations for medical devices with physiologic closed-loop control technology.

Medical Devices

Breakthrough for Central Venous Oxygenation Monitor

FDA grants Noninvasix a breakthrough device designation for its LivOx Central Venous Oxygenation Monitor for monitoring central venous oxygen saturati...

Federal Register

Meeting on Biosimilar User Fee Program Assessment

Federal Register notice: FDA announces a 3/22 virtual public meeting on the biosimilar user fee programs enhanced review transparency.